Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.08. | Evogene Q2 2025: Kostensenkungen federn verfehlte Umsatz- und Gewinnziele ab | 1 | Investing.com Deutsch | ||
19.08. | Evogene GAAP EPS of -$0.85 misses by $0.22, revenue of $0.88M misses by $0.05M | 1 | Seeking Alpha | ||
EVOGENE Aktie jetzt für 0€ handeln | |||||
19.08. | Evogene Reports Second Quarter 2025 Financial Results | 88 | PR Newswire | Conference call and webcast: today, August 19, 2025, 9:00 am ET
Financial Highlights:
The financial results for the first half of 2025 of Lavie Bio, a subsidiary... ► Artikel lesen | |
18.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
18.08. | Preview: Evogene's Earnings | 1 | Benzinga.com | ||
12.08. | Evogene startet KI-gestützte Forschungskooperation mit Universität Tel Aviv zur Behandlung von Stoffwechselerkrankungen | 2 | Investing.com Deutsch | ||
12.08. | Evogene partners with Tel Aviv University to develop metabolic disease treatments | 2 | Investing.com | ||
11.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
17.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
17.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
11.06. | Evogene, Google Cloud Launch AI Model For Breakthrough Small Molecule Discovery | 4 | RTTNews | ||
10.06. | Evogene Shares Surge On Completion Of Generative AI Foundation Model Developed With Google Cloud | 3 | RTTNews | ||
10.06. | Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud | 204 | PR Newswire | The new model addresses the challenge of identifying novel small molecules that meet multiple product criteria, an essential requirement for pharma and agriculture... ► Artikel lesen | |
05.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
22.05. | Evogene stock target cut to $3.50, maintains buy at Lake Street | 2 | Investing.com | ||
21.05. | Evogene GAAP EPS of -$0.38, revenue of $2.44M | 3 | Seeking Alpha | ||
21.05. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
21.05. | Evogene Reports First Quarter 2025 Financial Results | 107 | PR Newswire | Conference call and webcast: today, May 21, 2025, 9:00 am ET
Financial Highlights:
In the first quarter of 2025, total revenues were approximately $2.4 million... ► Artikel lesen | |
20.05. | Evogene Q1 2025 Earnings Preview | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
CUREVAC | 4,618 | +0,70 % | CureVac mit EILMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten warnen!!! | ||
MODERNA | 20,610 | +0,12 % | Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 | CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications... ► Artikel lesen | |
STRYKER | 333,50 | -0,36 % | Kurs von Stryker fällt ab (323,10 €) | Im Minus liegt gegenwärtig die Aktie von Stryker . Zuletzt zahlten Investoren für die Aktie 323,10 Euro. Für das Wertpapier von Stryker steht gegenwärtig ein Minus von 6,40 Prozent zu Buche. Das Papier... ► Artikel lesen | |
BIOGEN | 112,50 | -0,44 % | Milliardenmarkt Multiple Sklerose - BioNxt Solutions, Biogen, Merck KGaA, Novartis | Multiple Sklerose (MS) ist eine entzündliche und chronische Erkrankung des zentralen Nervensystems im Gehirn und Rückenmark des Menschen. Dabei greift das Immunsystem durch eine Fehlregulation die eigenen... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
REGENERON PHARMACEUTICALS | 494,00 | -0,48 % | Regeneron Pharmaceuticals, Inc.: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis | Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
INOVIO PHARMACEUTICALS | 1,980 | -1,98 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
SANGAMO THERAPEUTICS | 0,450 | +0,76 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen | |
INFLARX | 1,364 | +0,66 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 9,760 | +0,56 % | ARK Invest: Cathie Wood setzt auf Biotech-Wert Intellia und reduziert DraftKings-Position | ||
EDITAS MEDICINE | 2,149 | -2,01 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program... ► Artikel lesen | |
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |